Immunology Research Group, United States; Veterans Affairs Medical Center, United States.
Veterans Affairs Medical Center, United States; Department of Neurology, Oregon Health & Science University, Portland, OR 97239, United States.
J Neuroimmunol. 2014 Sep 15;274(1-2):46-52. doi: 10.1016/j.jneuroim.2014.06.011. Epub 2014 Jun 26.
We have used a peptide derived from Acanthamoeba castellanii (ACA) to treat the relapsing phase of EAE that develops in SJL mice following immunization with the PLP 139-151 peptide. The native sequence of the ACA 81-95 peptide that shares key residues with the PLP 139-151 peptide is weakly encephalitogenic in SJL mice but is not recognized by antiserum from SJL mice immunized with PLP 139-151. A single amino acid change to the ACA 81-95 peptide sequence significantly enhanced its encephalitogenicity. When administered to SJL mice as a nonlinear peptide octamer, the modified ACA peptide prevented relapsing episodes of EAE in SJL mice previously immunized with the PLP 139-151 encephalitogenic peptide.
我们使用源自嗜热变形菌（ACA）的肽段来治疗 SJL 小鼠在免疫 PLP 139-151 肽后出现的复发型 EAE。与 PLP 139-151 肽共享关键残基的 ACA 81-95 肽的天然序列在 SJL 小鼠中具有较弱的致脑炎性，但不能被用 PLP 139-151 免疫的 SJL 小鼠的抗血清识别。ACA 81-95 肽序列的单个氨基酸变化显著增强了其致脑炎性。当作为非线性肽八聚体施用于 SJL 小鼠时，修饰后的 ACA 肽可预防先前用 PLP 139-151 致脑炎肽免疫的 SJL 小鼠出现 EAE 的复发发作。
